David A. Siegel Acumen Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 392,100 shares of ABOS stock, worth $972,408. This represents 0.0% of its overall portfolio holdings.
Number of Shares
392,100
Previous 217,000
80.69%
Holding current value
$972,408
Previous $878,000
7.97%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ABOS
# of Institutions
84Shares Held
41.9MCall Options Held
239KPut Options Held
65.9K-
Ra Capital Management, L.P. Boston, MA14.9MShares$37 Million0.54% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$8.47 Million4.16% of portfolio
-
Franklin Resources Inc San Mateo, CA3.37MShares$8.35 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.3MShares$5.7 Million0.17% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$5.35 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $100M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...